Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes

Diabetologia

Volumn 43, Issue 3, 2000, Pages 377-383

  Gottschling Zeller, H ^a   Rohrig K ^a   Hauner, H ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Human adipocytes; Obesity; Plasminogen activator inhibitor 1; Troglitazone; Type II diabetes

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TROGLITAZONE;

ADIPOCYTE; ADULT; ARTICLE; CARDIOVASCULAR RISK; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS;

EID: 0034106767     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050057     Document Type: Article

References (32)

1. 1. Kissebah AH, Freedman DS, Peiris AN (1989) Health risks of obesity. Med Clin North Am 73: 111-138
2. 2. Juhan-Vague I, Alessi MC (1997) PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 78: 656-660
3. 3. De Pergola G, De Mitrio V, Giorgino F et al. (1997) Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. Int J Obes Relat Metab Disord 21: 527-535
4. 4. Janand-Delenne B, Chagnaud C, Raccah D, Alessi MC, Juhan-Vague I, Vague P (1998) Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord 22: 312-317
5. 5. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C (1989) Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism 38: 913-915
6. 6. Juhan-Vague I, Alessi MC, Vague P (1996) Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 28: 371-380
7. 7. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG on behalf of the ECAT Study Group (1996) Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 94: 2057-2063
8. 8. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE (1994) Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43: 104-109
9. 9. Schneider DJ, Sobel BE (1991) Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: Implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA 88: 9959-9963
10. 10. van Hingsberg VW, Kooistra T, van der Berg EA, Princen HM, Fiers W, Emeis JJ (1988) Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 72: 1467-1473
11. 11. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S (1996) Elaboration of type-1 plasminogen activator inhibitor from adipocytes. a potential pathogenic link between obesity and cardiovascular disease. Circulation 93: 106-110
12. 12. Samad F, Yamamoto K, Loskutoff DJ (1996) Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-α and lipopolysaccaride. J Clin Invest 97: 37-46
13. 13. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I (1997) Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes 46: 860-867
14. 14. Eriksson P, Reynisdottir S, Lönnqvist F, Stemme V, Hamsten A, Arner P (1998) Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 41: 65-71
15. 15. Shimomura I, Funahashi T, Takahashi M et al. (1996) Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 2: 800-803
16. 16. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J (1994) Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331: 1188-1193
17. 17. Kumar S, Boulton AJM, Beck-Nielsen H et al. for the Troglitazone study group (1996) Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39: 701-709
18. 18. Saltiel AR, Olefsky J (1996) Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45: 1661-1669
19. 19. Fonseca VA, Reynolds T, Hemphill D et al. (1998) Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 12: 181-186
20. 20. Ehrmann DA, Schneider DJ, Sobel BE et al. (1997) Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82: 2108-2116
21. 21. Kato K, Satoh H, Endo Yet al. (1999) Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells:a possible role for PPARγ in endothelial function. Biochem Biophys Res Commun 258: 431-435
22. 22. Hauner H, Entenmann G, Wabitsch M et al. (1989) Promoting effects of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest 84: 1663-1670
23. 23. Rodbell M (1964) Metabolism of isolated fat cell I. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 239: 375-380
24. 24. Chomczynsky P, Sacchi N (1987) Single-step method for isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159
25. 25. Wabitsch M, Jensen PB, Blum WF et al. (1996) Insulin and cortisol promote leptin production in cultures human fat cells. Diabetes 45: 1435-1438
26. 26. Entenmann G, Junger E, Gries FA, Hauner H (1994) Morphological characterization of human preadipocytes during in vitro adipoconversion under the control of insulin and cortisol. In: Ditschuneit H, Gries FA, Hauner H, Schusdziarra V, Wechsler JC (eds) Obesity in Europe 1993. John Libbey, London, pp 59-64
27. 27. Samad F, Uysal KT, Wiebrock SM, Pandey M, Hotamisligil GS, Loskutoff DJ (1999) Tumor necrosis factor a is a key component in the obesity-link elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 96: 6902-6907
28. 28. Spiegelman BM (1998) PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514
29. 29. Auboeuf D, Rieusset J, Fajas L et al. (1997) Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans. No alteration in adipose tissue of obese and NIDDM patients. Diabetes 46: 1319-1327
30. 30. Marx N, Bourcier T, Sokhova GK, Libby P, Plutzky J (1999) PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression:PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19: 546-551
31. 31. Lefebvre AM, Laville M, Vega N et al. (1998) Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 47: 98-103
32. 32. Montague CT, Prins JB, Sanders L et al. (1998) Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 47: 1384-1391